* Dermata Therapeutics Inc DRMA.OQ DRMA.O is expected
to show
no change in quarterly revenue when it reports results on March
20 (estimated) for the period ending December 31 2023
*
* LSEG's mean analyst estimate for Dermata Therapeutics Inc
is
for a loss of 78 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Dermata
Therapeutics Inc is $2.50, above its last closing price
of $0.40.
This summary was machine generated March 18 at 20:28 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)